Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | HTR1D | P28221 | 2/20 | 0.50 |
| ▸ | HTR1B | P28222 | 2/20 | 0.50 |
| ▸ | HTR1F | P30939 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL742626 | 0.92 | HTR6 (0.46) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL739874 | 0.84 | HTR6 (0.58) | HTR6DRD2DRD3 | |
| SCHEMBL742701 | 0.83 | HTR6 (0.62) | HTR6HTR1ADRD2 | |
| SCHEMBL742305 | 0.78 | HTR6 (0.54) | HTR6DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL742236 | 0.77 | HTR6 (0.53) | HTR6DRD2DRD3 | |
| Trifluoroacetic Acid SCHEMBL765583 | 0.77 | HTR6 (0.50) | HTR6DRD2DRD3 | |
| SCHEMBL740236 | 0.76 | HTR6 (0.57) | HTR6HTR1ADRD2DRD3 | |
| SCHEMBL741618 | 0.76 | HTR6 (0.57) | HTR6HTR1ADRD2DRD3 | |
| SCHEMBL741832 | 0.75 | HTR6 (0.48) | HTR6 | |
| Hydrochloric Acid SCHEMBL744058 | 0.75 | HTR6 (0.56) | HTR6HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459453-B2 | Pyridazin-3(2H)-one derivatives as PDE4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-12-02 | — | — | US | claimed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | claimed |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-03-09 | — | — | US | claimed |
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | DAL PIAZ VITTORIO | 2008-10-30 | — | — | US | disclosed |
| WO-2008110598-A1 | TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY | BIOVITRUM AB (PUBL) (SE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293694-A1 | New compounds | HTR6, HTR1A, HTR1B | HTR6 1/4885HTR1A 2/4885DRD2 40/4885 |
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE3A, PDE4B | HTR6 995/4885HTR1A 1051/4885DRD2 2790/4885 |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | PDE4A, PDE3A, PDE4B | HTR6 995/4885HTR1A 1051/4885DRD2 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.